Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

PURPOSE: Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progress...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Res Treat
Главные авторы: Lee, Kyoungmin, Bang, Kyunghye, Yoo, Changhoon, Hwang, Inhwan, Jeong, Jae Ho, Chang, Heung-Moon, Oh, Dongwook, Song, Tae Jun, Park, Do Hyun, Lee, Sang Soo, Lee, Sung Koo, Kim, Myung-Hwan, Park, Jin-hong, Kim, Kyu-pyo, Ryoo, Baek-Yeol
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Cancer Association 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6962478/
https://ncbi.nlm.nih.gov/pubmed/31291709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2019.190
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы